Healthcare System

180 Life Sciences – Clinical Programs

By healthprofessionalradio | Published December 1, 2020 | 3 min read

Dr. James (Jim) Woody, CEO of 180 Life Sciences Corp., a newly formed clinical-stage biotech company focused on novel drugs for unmet needs in inflammatory diseases, fibrosis, and pain, discusses three clinical programs using anti-TNF, with the lead program in Phase 2b/3 for Dupuytren’s contracture, a fibrotic disease of the hand. He previously led the team responsible for developing Remicade, the first of the TNF inhibitor biologics.

Frequently Asked Questions

What is the main topic discussed in this episode of Health Professional Radio?

This episode covers important developments in healthcare, including updates on Pain. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.

How can healthcare professionals benefit from this information?

Healthcare professionals can stay informed about the latest developments in Pain and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.

Where can I find more information about Pain?

For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.

</p> <div class="key-takeaways"> <h2 id="section-key-takeaways-5">Key Takeaways</h2> <ul> <li><strong>Key Point:</strong> James (Jim) Woody, CEO of 180 Life Sciences Corp., a newly formed clinical-stage biotech company focused on novel drugs for unmet needs in inflammatory diseases, fibrosis, and p…</li> <li><strong>Key Point:</strong> James Woody is Chief Executive Officer at 180 Life Sciences Corp., a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in i…</li> <li><strong>Key Point:</strong> Woody has more than 25 years of pharmaceutical research and management expertise.</li> <li><strong>Key Point:</strong> He currently serves as Chairman of Oncomed Pharmaceuticals, where he was previously a founder and CEO, and General Partner at Latterell Venture Partners, a venture capital group…</li> <li><strong>Key Point:</strong> Woody has served in a variety of health and management roles, including as President of Roche Bioscience and CSO and Senior Vice President of R&D for Centocor.</li> </ul> </div> <p>

Dr. James Woody is Chief Executive Officer at 180 Life Sciences Corp., a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain. Dr. Woody has more than 25 years of pharmaceutical research and management expertise. He currently serves as Chairman of Oncomed Pharmaceuticals, where he was previously a founder and CEO, and General Partner at Latterell Venture Partners, a venture capital group focusing on early-stage healthcare companies. Dr. Woody has served in a variety of health and management roles, including as President of Roche Bioscience and CSO and Senior Vice President of R&D for Centocor. He also served as Commanding Officer and Director at the U.S. Naval Medical Research and Development Command in Bethesda, Maryland. Dr. Woody earned his M.D. from Loma Linda University and his Ph.D. in Immunology from the University of London.

Health Professional Radio · 180 Life Sciences – Clinical Programs

Tags: 180 Life Sciences, Clinical Programs

healthprofessionalradio

Last updated: December 1, 2020

Medical Disclaimer

The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.